Soluble expression of an amebic cysteine protease in the cytoplasm of Escherichia coli SHuffle Express cells and purification of active enzyme
Tóm tắt
Recombinant production of amebic cysteine proteases using Escherichia coli cells as the bacterial system has become a challenging effort, with protein insolubility being the most common issue. Since many of these enzymes need a native conformation stabilized by disulfide bonds, an elaborate process of oxidative folding is usually demanded to get a functional protein. The cytoplasm of E. coli SHuffle Express cells owns an enhanced ability to properly fold proteins with disulfide bonds. Because of this cellular feature, it was possible to assume that this strain represents a reliable expression system and worthwhile been considered as an efficient bacterial host for the recombinant production of amebic cysteine proteases. Using E. coli SHuffle Express cells as the bacterial system, we efficiently produce soluble recombinant EhCP1protein. Enzymatic and inhibition analyses revealed that it exhibits proper catalytic abilities, proceeds effectively over the substrate (following an apparent Michaelis-Menten kinetics), and displays a typical inhibition profile. We report the first feasibility study of the recombinant production of amebic cysteine proteases using E. coli SHuffle Express as the bacterial host. We present a simple protocol for the recombinant expression and purification of fully soluble and active EhCP1 enzyme. We confirm the suitability of recombinant EhCP1 as a therapeutic target. We propose an approachable bacterial system for the recombinant production of amebic proteins, particularly for those with a need for proper oxidative folding.
Tài liệu tham khảo
Hooper NM. Proteases: a primer. Essays Biochem. 2002;38:1–8.
Neitzel JJ. Enzyme catalysis: the serine proteases. Nature Education. 2010;3:21.
Mótyán JA, Tóth F, Tőzsér J. Research applications of proteolytic enzymes in molecular biology. Biomol Ther. 2013;3:923–42.
Rawlings ND, Barrett AJ, Finn R. Twenty years of the MEROPS database of proteolytic enzymes, their substrates and inhibitors. Nucleic Acids Res. 2016;44(D1):D343–50.
Schrader EK, Harstad KG, Matouschek A. Targeting proteins for degradation. Nat Chem Biol. 2009;5:815–22.
Rub A, Arish M, Husain SA, et al. Host-lipidome as a potential target of protozoan parasites. Microbes Infect. 2013;15:649–60.
Andrews KT, Fisher G, Skinner-Adams TS. Drug repurposing and human parasitic protozoan diseases. Int J Parasitol Drugs Drug Resist. 2014;4:95–111.
Silva-Barrios S, Stäger S. Protozoan parasites and type I IFNs. Front Immunol. 2017;8:14.
Di Genova BM, Tonelli RR. Infection strategies of intestinal parasite pathogens and host cell responses. Front Microbiol. 2016;7:256.
Leitsch D. Recent advances in the Trichomonas vaginalis field. F1000Res. 2016;5.pii:F1000 Faculty Rev-162.
Atkinson HJ, Babbitt PC, Sajid M. The global cysteine peptidase landscape in parasites. Trends Parasitol. 2009;25:573–81.
Sibley LD. The roles of intramembrane proteases in protozoan parasites. Biochim Biophys Acta. 2013;1828:2908–15.
López-Otín C, Bond JS. Proteases: multifunctional enzymes in life and disease. J Biol Chem. 2008;283:30433–7.
Drag M, Salvesen GS. Emerging principles in protease-based drug discovery. Nat Rev Drug Discov. 2010;9:690–701.
Deu E, Verdoes M, Bogyo M. New approaches for dissecting protease functions to improve probe development and drug discovery. Nat Struct Mol Biol. 2012;19:9–16.
Cerdà-Costa N, Gomis-Rüth FX. Architecture and function of metallopeptidase catalytic domains. Protein Sci. 2014;23:123–44.
Marshall NC, Finlay BB, Overall CM. Sharpening host defenses during infection: proteases cut to the chase. Mol Cell Proteomics. 2017;16:S161–71.
Cornick S, Chadee K. Entamoeba histolytica: host parasite interactions at the colonic epithelium. Tissue Barriers. 2017;5:e1283386.
Tillack M, Biller L, Irmer H, et al. The Entamoeba histolytica genome: primary structure and expression of proteolytic enzymes. BMC Genomics. 2007;8:170.
Matthiesen J, Bär A-K, Bartels A-K, et al. Overexpression of specific cysteine peptidases confers pathogenicity to a nonpathogenic Entamoeba histolytica clone. MBio. 2013;4:e00072–13.
Ximénez C, González E, Nieves M, et al. Differential expression of pathogenic genes of Entamoeba histolytica vs E. dispar in a model of infection using human liver tissue explants. PLoS One. 2017;12:e0181962.
Bruchhaus I, Jacobs T, Leippe M, Tannich E. Entamoeba histolytica and Entamoeba dispar: differences in numbers and expression of cysteine proteinase genes. Mol Microbiol. 1996;22:255–63.
Serrano-Luna J, Piña-Vázquez C, Reyes-López M, et al. Proteases from Entamoeba spp. and pathogenic free-living amoebae as virulence factors. J Trop Med. 2013;2013:890603.
Meléndez-López SG, Herdman S, Hirata K, et al. Use of recombinant Entamoeba histolytica cysteine proteinase 1 to identify a potent inhibitor of amebic invasion in a human colonic model. Eukaryot Cell. 2007;6:1130–6.
Kato K, Makiuchi T, Cheng X, Tachibana H. Comparison of hemolytic activity of the intermediate subunit of Entamoeba histolytica and Entamoeba dispar lectins. PLoS One. 2017;12:e0181864.
Hellberg A, Nowak N, Leippe M, et al. Recombinant expression and purification of an enzymatically active cysteine proteinase of the protozoan parasite Entamoeba histolytica. Protein Expr Purif. 2002;24:131–7.
Quintas-Granados LI, Orozco E, Brieba LG, et al. Purification, refolding and autoactivation of the recombinant cysteine proteinase EhCP112 from Entamoeba histolytica. Protein Expr Purif. 2009;63:26–32.
He C, Nora GP, Schneider EL, et al. A novel Entamoeba histolytica cysteine proteinase, EhCP4, is key for invasive amebiasis and a therapeutic target. J Biol Chem. 2010;285:18516–27.
Zamudio-Prieto O, Benítez-Cardoza C, Arroyo R, Ortega-López J. Conformational changes induced by detergents during the refolding of chemically denatured cysteine protease ppEhCP-B9 from Entamoeba histolytica. Biochim Biophys Acta. 2014;1844:1299–306.
Lobstein J, Emrich CA, Jeans C, et al. SHuffle, a novel Escherichia coli protein expression strain capable of correctly folding disulfide bonded proteins in its cytoplasm. Microb Cell Factories. 2012;11:56.
Hashida S, Towatari T, Kominami E, Katunuma N. Inhibitions by E-64 derivatives of rat liver cathepsin B and cathepsin L in vitro and in vivo. J Biochem. 1980;88:1805–11.
Baird TT Jr, Wright WD, Craik CS. Conversion of trypsin to a functional threonine protease. Protein Sci. 2006;15:1229–38.
Que X, Kim S-H, Sajid M, et al. A surface amebic cysteine proteinase inactivates interleukin-18. Infect Immun. 2003;71:1274–80.
Hughes J, Rees S, Kalindjian S, Philpott K. Principles of early drug discovery. Br J Pharmacol. 2011;162:1239–49.
de Azevedo WF Jr, Soares MB. Selection of targets for drug development against protozoan parasites. Curr Drug Targets. 2009;10:193–201.
Fernández-Robledo JA, Vasta GR. Production of recombinant proteins from protozoan parasites. Trends Parasitol. 2010;26:244–54.
Wingfield PT. Overview of the purification of recombinant proteins. Curr Protoc Protein Sci. 2015;80:6.1.1–35.
Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning: A Laboratory Manual. 2nd ed. New York, NY, USA: Cold Spring Harbor Laboratory; 1989.
Zor T, Selinger Z. Linearization of the Bradford protein assay increases its sensitivity: theoretical and experimental studies. Anal Biochem. 1996;236:302–8.
Leippe M, Sievertsen HJ, Tannich E, Horstmann RD. Spontaneous release of cysteine proteinases but not of pore-forming peptides by viable Entamoeba histolytica. Parasitology. 1995;111:569–74.
Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970;227:680–5.
Serrano JJ, de la Garza M, Reyes M, et al. Entamoeba histolytica: proteinase secretion induced by collagen type I is dependent on cytoskeleton integrity. Parasitol Res. 1996;82:200–5.